Ilker Ates
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ilker Ates has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
Asuman Karakaya
Ankara University
8 shared publications- Halit Sinan Süzen
Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Ankara University, Ankara, Türkiye
6 shared publications - Lalu Muhammad Irham
Universitas Ahmad Dahlan
6 shared publications - Rockie Chong
Department of Chemistry and Biochemistry, University of California, Los Angeles, USA
4 shared publications - Asuman Karakaya
Department of Toxicology, Faculty of Pharmacy, Ankara University, Ankara, Turkey
3 shared publications Berran Yucesoy
Department of Toxicology, Faculty of Pharmacy, Ankara University, Tandogan, Ankara 06100, Turkey
3 shared publications
Latest Publications
- 7 November 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Collaboration between clinical pharmacists and physicians to manage drug-related problems in an adult hematopoietic stem cell transplantation unit
Introduction: This study aimed to determine drug-related problems and identify potential solution in collaboration with clinical pharmacists and specialist physicians at an adult hematopoietic stem cell transplantation unit in Türkiye. Methods: This is a prospective observational study that included patients with autologous and allogeneic HSCT (Hematopoietic Stem cell Transplantation) admitted to a university hospital HSCT unit in Türkiye due to the disease or complications between June 2023 and January 2024. Drug-related problems (DRPs) were identified during a comprehensive medication review performed by a single clinical pharmacist (specialist trainee) supervised by a senior clinical pharmacist, using the Turkish version of the v.9.1 Pharmaceutical Care Network Europe (PCNE) classification. The potential DRPs were reported to the physicians to discuss their agreement on the possible solutions. The number of DRPs, agreement rate of the solutions and status of interventions were recorded. Results: The study enrolled 66 adult patients with a median age of 54.5 years (54.5% male). A total of 156 potential DRPs were identified among the patients at HSCTU with an average of 2.4 DRPs per patient. The proportion of patients experiencing at least one DRP was 89% in the autologous HSCT group and 97% in the allogeneic HSCT group. Patients with allogeneic HSCT experienced a significantly higher number of DRPs compared to those with autologous HSCT. Among DRPs, drug-drug interactions (DDIs) were common (56.0%). The majority of the recommendations made by the clinical pharmacist in training were accepted by the physicians (86.5%). Overall, 84.0% of DRPs were solved in collaboration with clinical pharmacists and physicians. Conclusions: DDIs were common DRPs among patients with HSCT. Most of the clinical pharmacists’ recommendations were accepted. A substantial number of potential DRPs were effectively resolved through direct collaboration between the clinical pharmacist and physicians.
- 7 November 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Collaboration between clinical pharmacists and physicians to manage drug-related problems in an adult hematopoietic stem cell transplantation unit
Introduction: This study aimed to determine drug-related problems and identify potential solution in collaboration with clinical pharmacists and specialist physicians at an adult hematopoietic stem cell transplantation unit in Türkiye. Methods: This is a prospective observational study that included patients with autologous and allogeneic HSCT (Hematopoietic Stem cell Transplantation) admitted to a university hospital HSCT unit in Türkiye due to the disease or complications between June 2023 and January 2024. Drug-related problems (DRPs) were identified during a comprehensive medication review performed by a single clinical pharmacist (specialist trainee) supervised by a senior clinical pharmacist, using the Turkish version of the v.9.1 Pharmaceutical Care Network Europe (PCNE) classification. The potential DRPs were reported to the physicians to discuss their agreement on the possible solutions. The number of DRPs, agreement rate of the solutions and status of interventions were recorded. Results: The study enrolled 66 adult patients with a median age of 54.5 years (54.5% male). A total of 156 potential DRPs were identified among the patients at HSCTU with an average of 2.4 DRPs per patient. The proportion of patients experiencing at least one DRP was 89% in the autologous HSCT group and 97% in the allogeneic HSCT group. Patients with allogeneic HSCT experienced a significantly higher number of DRPs compared to those with autologous HSCT. Among DRPs, drug-drug interactions (DDIs) were common (56.0%). The majority of the recommendations made by the clinical pharmacist in training were accepted by the physicians (86.5%). Overall, 84.0% of DRPs were solved in collaboration with clinical pharmacists and physicians. Conclusions: DDIs were common DRPs among patients with HSCT. Most of the clinical pharmacists’ recommendations were accepted. A substantial number of potential DRPs were effectively resolved through direct collaboration between the clinical pharmacist and physicians.
- Open Access
- 2 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1988777
Correction: Modulating Nrf2 to control lipid peroxidation and ferroptosis: implications for cancer management
Lipid peroxidation (LP) represents a fundamental mechanism of oxidative damage of fatty acids, typically polyunsaturated fatty acids (PUFAs), in cellular membranes and occurs when reactive oxygen species (ROS) extract a hydrogen atom from bis-allylic methylene groups, generating lipid radicals. These radicals react with molecular oxygen to form lipid peroxyl radicals, which in turn propagate the chain reaction by attacking adjacent lipids. The process culminates in the accumulation of lipid hydroperoxides and reactive aldehydes, such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), which disrupt membrane architecture, impair protein function, and trigger cell death pathways (1).Ferroptosis is critically dependent on this process. Unlike other forms of cell death, such as apoptosis or necrosis, ferroptosis is defined by the accumulation of lipid peroxides beyond the detoxification capacity of the cell. The failure of antioxidant systems, particularly glutathione peroxidase 4 (GPX4), which reduces lipid hydroperoxides to non-toxic lipid alcohols, leads to the collapse of membrane integrity and ferroptotic cell death (2,3). As such, lipid peroxidation is not merely associated with ferroptosis but serves as both a trigger and a modulator, positioning LP as a mechanistic hallmark of this form of cell death. This process is particularly relevant in therapy-resistant tumors, in which ferroptosis activation has shown potential to overcome resistance mechanisms. Furthermore, ferroptosis is involved in the pathogenesis of several degenerative diseases associated with oxidative stress (OS), highlighting its therapeutic relevance (4).A central regulator of ferroptosis and oxidative stress responses is nuclear factor erythroid 2related factor 2 (Nrf2), a transcription factor that controls the expression of a wide array of antioxidant and cytoprotective genes. Nrf2 plays a pivotal role in redox homeostasis and is involved in key metabolic processes, including xenobiotic detoxification, iron and heme metabolism, lipid and carbohydrate metabolism, proteostasis, and the regulation of cell death pathways (5).The activity of Nrf2 is primarily regulated by Kelch-like ECH-associated protein 1 (Keap1), a cytosolic repressor that acts as a substrate adaptor for a Cullin-3-based E3 ubiquitin ligase complex. Under basal conditions, Keap1 binds Nrf2 and promotes its proteasomal degradation, thereby limiting its transcriptional activity. Upon exposure to oxidative or electrophilic stress, critical cysteine residues on Keap1 are modified, resulting in the stabilization and nuclear accumulation of Nrf2. Once in the nucleus, Nrf2 binds to antioxidant response elements (AREs) and induces the expression of target genes involved in glutathione synthesis, iron sequestration, and detoxification of lipid peroxides (6).In the cancer context, aberrant activation of the Nrf2 is frequently observed and contributes to tumor progression by counteracting lipid peroxidation and ferroptosis. Many tumor types, including lung, liver, and head and neck carcinomas, harbor mutations in KEAP1 or NRF2 that lead to sustained Nrf2 activity. This persistent activation enhances the antioxidant and ironsequestering capacity of cancer cells, promoting glutathione synthesis, increasing the expression of ferroptosis-suppressor proteins, and reducing free iron availability (7). As a result, these cells acquire a metabolic advantage that allows them to resist high levels of ROS and evade ferroptotic cell death. While this mechanism protects normal cells from oxidative damage under stress, in cancer, it facilitates proliferation, chemoresistance, and immune evasion. However, Nrf2 does not play a uniformly oncogenic role. In the early stages of oncogenesis, transient activation of Nrf2 can exert tumor-suppressive effects by enhancing the antioxidant response, limiting genomic instability, and promoting the elimination of transformed or damaged cells. This suggests a context-dependent function, where Nrf2 initially acts as a guardian against malignant transformation but may later be co-opted by cancer cells to support their survival and resistance. This duality poses both challenges and opportunities: inhibiting Nrf2 may sensitize cancer cells to ferroptosis inducers, whereas activating Nrf2 may offer protection in non-neoplastic diseases driven by ferroptosis and oxidative stress (8).Lipid peroxidation (LP) is a defining feature of oxidative damage and a central mediator of ferroptosis. It involves the oxidative degradation of polyunsaturated fatty acids (PUFAs) within cellular membranes. Triggered by reactive oxygen species (ROS), the process begins with hydrogen abstraction from bis-allylic methylene groups, producing lipid radicals that react with molecular oxygen to form lipid peroxyl radicals. These radicals propagate the chain reaction, leading to the accumulation of lipid hydroperoxides (LOOHs) and reactive aldehydes such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE). These byproducts destabilize membranes, disrupt protein function, and activate pro-death signaling. Mitochondrial and plasma membranes, enriched in PUFAs, are particularly susceptible under conditions of iron overload and impaired antioxidant defense (9).LP is tightly linked to the cellular redox state. Alongside lipid radicals, cells under oxidative stress generate diverse ROS and reactive nitrogen species (RNS) capable of damaging lipids, proteins, and nucleic acids. Chronic oxidative stress, driven by metabolic or environmental factors, amplifies LP and activates regulated cell death pathways, including ferroptosis (10)(11)(12).Despite their high reactivity, ROS and RNS also function as signaling molecules in processes such as proliferation, immunity, inflammation, and autophagy. This dual nature, balancing signaling and damage, remains a subject of intense debate (13)(14)(15). ROS include radical species (O₂•⁻, •OH, RO•,...
- 2 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1988777
Open AccessCorrection: Modulating Nrf2 to control lipid peroxidation and ferroptosis: implications for cancer management
Lipid peroxidation (LP) represents a fundamental mechanism of oxidative damage of fatty acids, typically polyunsaturated fatty acids (PUFAs), in cellular membranes and occurs when reactive oxygen species (ROS) extract a hydrogen atom from bis-allylic methylene groups, generating lipid radicals. These radicals react with molecular oxygen to form lipid peroxyl radicals, which in turn propagate the chain reaction by attacking adjacent lipids. The process culminates in the accumulation of lipid hydroperoxides and reactive aldehydes, such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), which disrupt membrane architecture, impair protein function, and trigger cell death pathways (1).Ferroptosis is critically dependent on this process. Unlike other forms of cell death, such as apoptosis or necrosis, ferroptosis is defined by the accumulation of lipid peroxides beyond the detoxification capacity of the cell. The failure of antioxidant systems, particularly glutathione peroxidase 4 (GPX4), which reduces lipid hydroperoxides to non-toxic lipid alcohols, leads to the collapse of membrane integrity and ferroptotic cell death (2,3). As such, lipid peroxidation is not merely associated with ferroptosis but serves as both a trigger and a modulator, positioning LP as a mechanistic hallmark of this form of cell death. This process is particularly relevant in therapy-resistant tumors, in which ferroptosis activation has shown potential to overcome resistance mechanisms. Furthermore, ferroptosis is involved in the pathogenesis of several degenerative diseases associated with oxidative stress (OS), highlighting its therapeutic relevance (4).A central regulator of ferroptosis and oxidative stress responses is nuclear factor erythroid 2related factor 2 (Nrf2), a transcription factor that controls the expression of a wide array of antioxidant and cytoprotective genes. Nrf2 plays a pivotal role in redox homeostasis and is involved in key metabolic processes, including xenobiotic detoxification, iron and heme metabolism, lipid and carbohydrate metabolism, proteostasis, and the regulation of cell death pathways (5).The activity of Nrf2 is primarily regulated by Kelch-like ECH-associated protein 1 (Keap1), a cytosolic repressor that acts as a substrate adaptor for a Cullin-3-based E3 ubiquitin ligase complex. Under basal conditions, Keap1 binds Nrf2 and promotes its proteasomal degradation, thereby limiting its transcriptional activity. Upon exposure to oxidative or electrophilic stress, critical cysteine residues on Keap1 are modified, resulting in the stabilization and nuclear accumulation of Nrf2. Once in the nucleus, Nrf2 binds to antioxidant response elements (AREs) and induces the expression of target genes involved in glutathione synthesis, iron sequestration, and detoxification of lipid peroxides (6).In the cancer context, aberrant activation of the Nrf2 is frequently observed and contributes to tumor progression by counteracting lipid peroxidation and ferroptosis. Many tumor types, including lung, liver, and head and neck carcinomas, harbor mutations in KEAP1 or NRF2 that lead to sustained Nrf2 activity. This persistent activation enhances the antioxidant and ironsequestering capacity of cancer cells, promoting glutathione synthesis, increasing the expression of ferroptosis-suppressor proteins, and reducing free iron availability (7). As a result, these cells acquire a metabolic advantage that allows them to resist high levels of ROS and evade ferroptotic cell death. While this mechanism protects normal cells from oxidative damage under stress, in cancer, it facilitates proliferation, chemoresistance, and immune evasion. However, Nrf2 does not play a uniformly oncogenic role. In the early stages of oncogenesis, transient activation of Nrf2 can exert tumor-suppressive effects by enhancing the antioxidant response, limiting genomic instability, and promoting the elimination of transformed or damaged cells. This suggests a context-dependent function, where Nrf2 initially acts as a guardian against malignant transformation but may later be co-opted by cancer cells to support their survival and resistance. This duality poses both challenges and opportunities: inhibiting Nrf2 may sensitize cancer cells to ferroptosis inducers, whereas activating Nrf2 may offer protection in non-neoplastic diseases driven by ferroptosis and oxidative stress (8).Lipid peroxidation (LP) is a defining feature of oxidative damage and a central mediator of ferroptosis. It involves the oxidative degradation of polyunsaturated fatty acids (PUFAs) within cellular membranes. Triggered by reactive oxygen species (ROS), the process begins with hydrogen abstraction from bis-allylic methylene groups, producing lipid radicals that react with molecular oxygen to form lipid peroxyl radicals. These radicals propagate the chain reaction, leading to the accumulation of lipid hydroperoxides (LOOHs) and reactive aldehydes such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE). These byproducts destabilize membranes, disrupt protein function, and activate pro-death signaling. Mitochondrial and plasma membranes, enriched in PUFAs, are particularly susceptible under conditions of iron overload and impaired antioxidant defense (9).LP is tightly linked to the cellular redox state. Alongside lipid radicals, cells under oxidative stress generate diverse ROS and reactive nitrogen species (RNS) capable of damaging lipids, proteins, and nucleic acids. Chronic oxidative stress, driven by metabolic or environmental factors, amplifies LP and activates regulated cell death pathways, including ferroptosis (10)(11)(12).Despite their high reactivity, ROS and RNS also function as signaling molecules in processes such as proliferation, immunity, inflammation, and autophagy. This dual nature, balancing signaling and damage, remains a subject of intense debate (13)(14)(15). ROS include radical species (O₂•⁻, •OH, RO•,...
- Open Access
- 31 March 2026
- Published by Universitas Ahmad Dahlan in Media Farmasi: Jurnal Ilmu Farmasi
- Vol. 23 (1) , 52-62
Integrative PharmGKB and GTEx Analysis Identifies Candidate Pharmacogenomic Biomarkers of Toxicity in Thyroid Cancer Therapy
Systemic therapies such as Lenvatinib and radioiodine in thyroid cancer (TC) show promising clinical efficacy, but often cause significant toxicity. Interindividual variability in response to this toxicity is largely influenced by genetic factors, requiring a pharmacogenomic approach to accurately identify predictive biomarkers. This study aims to integrate pharmacogenomic and bioinformatics strategies in identifying genetic variants associated with the risk of TC therapy toxicity. The research method involved a systematic search of the PharmGKB database using the keyword “Thyroid Cancer.” The selection results were filtered based on clinical pharmacogenomic relevance and ESMO therapy guidelines. Only gene-drug pairs with Level of Evidence (LOE) 1A to 3 were included. Furthermore, genetic variant data were analyzed bioinformatically based on tissue expression profiles and biological relevance. The results of the study of three main systemic therapies (lenvatinib, sorafenib, and radioiodine) identified two biomarkers with LOE level 3: the rs776746 (CYP3A5) variant associated with lenvatinib toxicity, and rs620815 (ATM) associated with gastrointestinal toxicity due to radioiodine. Tissue expression analysis showed CYP3A5 to be dominant in the liver and intestines, supporting its role in drug metabolism, while ATM was widely expressed and involved in DNA repair. Both genes have potential as predictive biomarkers of TC therapy toxicity. This study demonstrates that the integration of pharmacogenomic and bioinformatics approaches can identify potential genetic biomarkers contributing to the risk of TC therapy toxicity. These findings strengthen the basis for the application of genetic-based precision medicine in optimizing the safety and individualization of TC therapy.
- 31 March 2026
- Published by Universitas Ahmad Dahlan in Media Farmasi: Jurnal Ilmu Farmasi
- Vol. 23 (1) , 52-62
Open AccessIntegrative PharmGKB and GTEx Analysis Identifies Candidate Pharmacogenomic Biomarkers of Toxicity in Thyroid Cancer Therapy
Systemic therapies such as Lenvatinib and radioiodine in thyroid cancer (TC) show promising clinical efficacy, but often cause significant toxicity. Interindividual variability in response to this toxicity is largely influenced by genetic factors, requiring a pharmacogenomic approach to accurately identify predictive biomarkers. This study aims to integrate pharmacogenomic and bioinformatics strategies in identifying genetic variants associated with the risk of TC therapy toxicity. The research method involved a systematic search of the PharmGKB database using the keyword “Thyroid Cancer.” The selection results were filtered based on clinical pharmacogenomic relevance and ESMO therapy guidelines. Only gene-drug pairs with Level of Evidence (LOE) 1A to 3 were included. Furthermore, genetic variant data were analyzed bioinformatically based on tissue expression profiles and biological relevance. The results of the study of three main systemic therapies (lenvatinib, sorafenib, and radioiodine) identified two biomarkers with LOE level 3: the rs776746 (CYP3A5) variant associated with lenvatinib toxicity, and rs620815 (ATM) associated with gastrointestinal toxicity due to radioiodine. Tissue expression analysis showed CYP3A5 to be dominant in the liver and intestines, supporting its role in drug metabolism, while ATM was widely expressed and involved in DNA repair. Both genes have potential as predictive biomarkers of TC therapy toxicity. This study demonstrates that the integration of pharmacogenomic and bioinformatics approaches can identify potential genetic biomarkers contributing to the risk of TC therapy toxicity. These findings strengthen the basis for the application of genetic-based precision medicine in optimizing the safety and individualization of TC therapy.
- Open Access
- 3 December 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1701249
Modulating Nrf2 to control lipid peroxidation and ferroptosis: implications for cancer management
Nuclear factor erythroid 2–related factor 2 (Nrf2) is a key transcription factor that regulates the expression of genes involved in cellular protection against oxidative stress and the maintenance of redox homeostasis. In addition to modulating reactive oxygen species (ROS), Nrf2 influences lipid peroxidation (LP) and ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxide accumulation. Dysregulation of Nrf2 signaling has been implicated in the pathogenesis and progression of several malignancies, where it affects tumor cell survival, chemoresistance, and metabolic reprogramming. This review summarizes current knowledge on the complex relationship between Nrf2 activity, LP dynamics, and ferroptotic mechanisms in cancer biology. It also highlights how Nrf2-dependent transcriptional programs not only regulate antioxidant responses but also contribute to cellular detoxification, metabolism, autophagy, and proteostasis, processes closely linked to tumorigenesis and cancer cell adaptability. Given that Nrf2 may have a dual role in cancer, either promoting cytoprotection or supporting tumor progression and chemoresistance, we discuss emerging strategies to selectively modulate Nrf2 and ferroptosis-related pathways to increase cancer cell sensitivity to oxidative damage and reduce resistance.
- 3 December 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1701249
Open AccessModulating Nrf2 to control lipid peroxidation and ferroptosis: implications for cancer management
Nuclear factor erythroid 2–related factor 2 (Nrf2) is a key transcription factor that regulates the expression of genes involved in cellular protection against oxidative stress and the maintenance of redox homeostasis. In addition to modulating reactive oxygen species (ROS), Nrf2 influences lipid peroxidation (LP) and ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxide accumulation. Dysregulation of Nrf2 signaling has been implicated in the pathogenesis and progression of several malignancies, where it affects tumor cell survival, chemoresistance, and metabolic reprogramming. This review summarizes current knowledge on the complex relationship between Nrf2 activity, LP dynamics, and ferroptotic mechanisms in cancer biology. It also highlights how Nrf2-dependent transcriptional programs not only regulate antioxidant responses but also contribute to cellular detoxification, metabolism, autophagy, and proteostasis, processes closely linked to tumorigenesis and cancer cell adaptability. Given that Nrf2 may have a dual role in cancer, either promoting cytoprotection or supporting tumor progression and chemoresistance, we discuss emerging strategies to selectively modulate Nrf2 and ferroptosis-related pathways to increase cancer cell sensitivity to oxidative damage and reduce resistance.
- Open Access
- 8 November 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (11) , 1698
Modulation of Nrf2 and Mitochondrial Function: Pharmacological Implications
Mammalians are constantly exposed to exogenous and endogenous sources of free radicals that have both favorable and harmful effects on the cellular systems. Oxidative stress (OS) is an imbalance of reactive oxygen species (ROS) and antioxidants in the body that can lead to serious cell damage. It is associated with many diseases such as cancer, Alzheimer’s disease and heart disease. Background/Objectives: The Nuclear factor-2 erythroid-related factor-2 (Nrf2) is a transcription factor that controls the cellular oxidation state using antioxidant systems in the body and affects mitochondrial activities. Increased Nrf2 levels serve to protect cells from mitochondrial toxins; however, Nrf2 activity is inhibited in mitochondria-related diseases. In addition, Nrf2 is involved in mitochondrial activities for OS control. Methods: As mitochondrial wellbeing and activity is the chief controller for cellular metabolism, Nrf2 is a critical regulator for metabolic pathways. Thus, Nrf2 is the chief organizer of protection against OS in the cells. Nrf2 activator molecules support mitochondrial activity by stimulating mitophagy and helping to battle OS-related permeability transition. Conclusions: This review describes the influence of Nrf2 on OS and the way Nrf2 modulates mitochondrial function. Furthermore, we highlight recent studies of Nrf2 regarding its possible role in cell systems as well as pharmacological implications. Furthermore, this review emphasizes the importance of the mitochondria in the development of life-threatening diseases; pharmacological activation of Nrf2 is an important strategy to counter mitochondrial dysfunction
- 8 November 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (11) , 1698
Open AccessModulation of Nrf2 and Mitochondrial Function: Pharmacological Implications
Mammalians are constantly exposed to exogenous and endogenous sources of free radicals that have both favorable and harmful effects on the cellular systems. Oxidative stress (OS) is an imbalance of reactive oxygen species (ROS) and antioxidants in the body that can lead to serious cell damage. It is associated with many diseases such as cancer, Alzheimer’s disease and heart disease. Background/Objectives: The Nuclear factor-2 erythroid-related factor-2 (Nrf2) is a transcription factor that controls the cellular oxidation state using antioxidant systems in the body and affects mitochondrial activities. Increased Nrf2 levels serve to protect cells from mitochondrial toxins; however, Nrf2 activity is inhibited in mitochondria-related diseases. In addition, Nrf2 is involved in mitochondrial activities for OS control. Methods: As mitochondrial wellbeing and activity is the chief controller for cellular metabolism, Nrf2 is a critical regulator for metabolic pathways. Thus, Nrf2 is the chief organizer of protection against OS in the cells. Nrf2 activator molecules support mitochondrial activity by stimulating mitophagy and helping to battle OS-related permeability transition. Conclusions: This review describes the influence of Nrf2 on OS and the way Nrf2 modulates mitochondrial function. Furthermore, we highlight recent studies of Nrf2 regarding its possible role in cell systems as well as pharmacological implications. Furthermore, this review emphasizes the importance of the mitochondria in the development of life-threatening diseases; pharmacological activation of Nrf2 is an important strategy to counter mitochondrial dysfunction
- Open Access
- 22 July 2025
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 137 (2) , e70082
The Role of Hydroxychloroquine in the Management of Rheumatic Disorders: A Comprehensive Review
A drug preferred for its antimalarial effect called hydroxychloroquine (HCQ) has long been used to manage and avoid malaria. Nevertheless, its exact mode of action is still unknown. HCQ works through a variety of strategies to influence distinct molecular and cellular pathways. Additionally, HCQ has been demonstrated to be an effective treatment for rheumatic conditions such as primary Sjögren's syndrome, rheumatoid arthritis, antiphospholipid syndrome and systemic lupus erythematosus. Despite being widely regarded as safe, HCQ has been known to cause adverse responses; thus, doctors should closely evaluate rheumatism patients before taking these medications. The current study aims to emphasize the potential side effects of treatment while supporting the clinical usage of HCQ for autoimmune disorders.
- 22 July 2025
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 137 (2) , e70082
Open AccessThe Role of Hydroxychloroquine in the Management of Rheumatic Disorders: A Comprehensive Review
A drug preferred for its antimalarial effect called hydroxychloroquine (HCQ) has long been used to manage and avoid malaria. Nevertheless, its exact mode of action is still unknown. HCQ works through a variety of strategies to influence distinct molecular and cellular pathways. Additionally, HCQ has been demonstrated to be an effective treatment for rheumatic conditions such as primary Sjögren's syndrome, rheumatoid arthritis, antiphospholipid syndrome and systemic lupus erythematosus. Despite being widely regarded as safe, HCQ has been known to cause adverse responses; thus, doctors should closely evaluate rheumatism patients before taking these medications. The current study aims to emphasize the potential side effects of treatment while supporting the clinical usage of HCQ for autoimmune disorders.
- 26 February 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 259, 116763
Exploring efavirenz-DNA interactions: A multidisciplinary approach through electrochemical, toxicological, and in silico investigations
- 26 February 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 259, 116763
Exploring efavirenz-DNA interactions: A multidisciplinary approach through electrochemical, toxicological, and in silico investigations
- Open Access
- 25 February 2025
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 24, 289-320
Rhoifolin: A promising flavonoid with potent cytotoxic and anticancer properties
Rhoifolin is a flavonoid found in various plant species, especially within the Rutaceae family, and is considered a dietary component due to its presence in edible plants. Its bioactive properties, such as cytotoxic and anticancer activities, have gained significant attention. This review aims to highlight the general properties and diverse bioactivities of rhoifolin, with a particular focus on its cytotoxic and anticancer effects. This is based on a comprehensive literature search, focusing on the presence of rhoifolin in different plant species and its biological activities, particularly its anticancer properties. Rhoifolin is widely distributed in the plant kingdom, especially in Citrus species. It exhibits a variety of bioactivities, including strong cytotoxic and anticancer effects. Recent studies have shown that rhoifolin can induce apoptosis and inhibit cancer cell proliferation, making it a promising candidate for anticancer therapies. Rhoifolin's diverse bioactivities, particularly its cytotoxic and anticancer properties, position it as a potential therapeutic agent. Further detailed investigations into its molecular mechanisms and well-designed clinical studies are needed to fully understand and utilize its therapeutic potential.
- 25 February 2025
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 24, 289-320
Open AccessRhoifolin: A promising flavonoid with potent cytotoxic and anticancer properties
Rhoifolin is a flavonoid found in various plant species, especially within the Rutaceae family, and is considered a dietary component due to its presence in edible plants. Its bioactive properties, such as cytotoxic and anticancer activities, have gained significant attention. This review aims to highlight the general properties and diverse bioactivities of rhoifolin, with a particular focus on its cytotoxic and anticancer effects. This is based on a comprehensive literature search, focusing on the presence of rhoifolin in different plant species and its biological activities, particularly its anticancer properties. Rhoifolin is widely distributed in the plant kingdom, especially in Citrus species. It exhibits a variety of bioactivities, including strong cytotoxic and anticancer effects. Recent studies have shown that rhoifolin can induce apoptosis and inhibit cancer cell proliferation, making it a promising candidate for anticancer therapies. Rhoifolin's diverse bioactivities, particularly its cytotoxic and anticancer properties, position it as a potential therapeutic agent. Further detailed investigations into its molecular mechanisms and well-designed clinical studies are needed to fully understand and utilize its therapeutic potential.